BioCryst Pharmaceuticals (BCRX) News Today → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free BCRX Stock Alerts $6.46 -0.11 (-1.67%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 2 at 4:00 AM | globenewswire.comBioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) TreatmentJune 1 at 9:37 AM | insidertrades.comInsider Buying: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Buys 7,861 Shares of StockMay 31 at 4:58 PM | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Purchases $49,995.96 in StockBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Alan G. Levin bought 7,861 shares of the stock in a transaction on Thursday, May 30th. The stock was acquired at an average price of $6.36 per share, with a total value of $49,995.96. Following the completion of the acquisition, the director now owns 44,951 shares of the company's stock, valued at approximately $285,888.36. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.May 31 at 7:46 AM | americanbankingnews.comSteve Aselage Purchases 2,500 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) StockMay 31 at 4:21 AM | marketbeat.comCharles Schwab Investment Management Inc. Raises Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Charles Schwab Investment Management Inc. boosted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 9.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,594,436 shares of the biotecMay 30 at 8:39 AM | insidertrades.comInsider Buying: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Buys 2,500 Shares of StockMay 29, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Acquires $16,000.00 in StockBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Steve Aselage bought 2,500 shares of the stock in a transaction on Friday, May 24th. The shares were acquired at an average price of $6.40 per share, with a total value of $16,000.00. Following the purchase, the director now owns 2,500 shares of the company's stock, valued at $16,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.May 29, 2024 | finance.yahoo.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near FutureMay 29, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Aigen Investment Management LPAigen Investment Management LP decreased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 91.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 12,670 shares of the biotechnology company's stock after selling 1May 26, 2024 | marketbeat.comTrexquant Investment LP Has $2.53 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Trexquant Investment LP decreased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 28.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 421,516 shares of the biotechnology company's stMay 25, 2024 | benzinga.comBioCryst Pharma Stock (NASDAQ:BCRX), Quotes and News SummaryMay 25, 2024 | americanbankingnews.comInsider Buying: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Buys $31,900.00 in StockMay 23, 2024 | insidertrades.comNancy J. Hutson Purchases 5,000 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) StockMay 23, 2024 | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Insider Buying ActivityMay 22, 2024 | marketbeat.comGW&K Investment Management LLC Sells 233,180 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)GW&K Investment Management LLC reduced its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 9.1% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,337,683 shares of the biotechnology company'sMay 22, 2024 | marketbeat.comNancy J. Hutson Buys 5,000 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) StockBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Nancy J. Hutson acquired 5,000 shares of the company's stock in a transaction on Monday, May 20th. The shares were bought at an average cost of $6.38 per share, with a total value of $31,900.00. Following the acquisition, the director now directly owns 86,818 shares in the company, valued at $553,898.84. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.May 21, 2024 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 4.4% Higher BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 4.4%May 21, 2024 | marketbeat.comBNP Paribas Financial Markets Boosts Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)BNP Paribas Financial Markets increased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 45.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 790,163 shares of the biotechnology company's stock after purchasing an additional 247,195May 20, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Assenagon Asset Management S.A.Assenagon Asset Management S.A. cut its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 26.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 386,885 shares of the biotechnoloMay 20, 2024 | marketbeat.comJump Financial LLC Has $771,000 Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Jump Financial LLC cut its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 68.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 128,771 shares of the biotechnology cMay 16, 2024 | insidertrades.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Steven K. Galson Buys 21,940 SharesMay 15, 2024 | finance.yahoo.comInsider Buying: CFO Anthony Doyle Acquires Shares of BioCryst Pharmaceuticals Inc (BCRX)May 15, 2024 | finance.yahoo.comInsider Buying: Charles Gayer Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX)May 15, 2024 | finance.yahoo.comDirector Steven Galson Acquires 21,940 Shares of BioCryst Pharmaceuticals Inc (BCRX)May 15, 2024 | finance.yahoo.comInsider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst ...May 15, 2024 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up on Insider Buying ActivityBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up on Insider Buying ActivityMay 15, 2024 | seekingalpha.comBioCryst Pharmaceuticals, T2 Biosystems, Annovis Bio among healthcare moversMay 15, 2024 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Steven K. Galson Purchases 21,940 SharesBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Steven K. Galson purchased 21,940 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, May 13th. The shares were acquired at an average cost of $5.49 per share, with a total value of $120,450.60. Following the transaction, the director now directly owns 51,551 shares in the company, valued at $283,014.99. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.May 14, 2024 | globenewswire.comBioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical ImmunologyMay 13, 2024 | markets.businessinsider.comBiocryst Pharma's Orladeyo Approved In Mexico For Hereditary Angioedema AttacksMay 13, 2024 | globenewswire.comORLADEYO® (berotralstat) Approved in MexicoMay 9, 2024 | finance.yahoo.comAnalysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its First-Quarter ResultsMay 9, 2024 | finance.yahoo.comBioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)May 9, 2024 | globenewswire.comBioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)May 9, 2024 | marketbeat.comEquities Analysts Issue Forecasts for BioCryst Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:BCRX)BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Research analysts at HC Wainwright upped their Q2 2024 earnings per share (EPS) estimates for BioCryst Pharmaceuticals in a research report issued on Tuesday, May 7th. HC Wainwright analyst A. Fein now forecasts that the biotechnology cMay 8, 2024 | marketbeat.comFY2028 EPS Estimates for BioCryst Pharmaceuticals, Inc. Decreased by Analyst (NASDAQ:BCRX)BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Stock analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for BioCryst Pharmaceuticals in a report issued on Tuesday, May 7th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company wiMay 7, 2024 | markets.businessinsider.comBuy Rating for BioCryst’s Orladeyo: Poised for Pediatric Market Growth and Continued HAE Market PenetrationMay 7, 2024 | bizjournals.comWhy this RTP public company expects big revenue gains in 2024May 7, 2024 | finance.yahoo.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call TranscriptMay 7, 2024 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $15.00 at JMP SecuritiesJMP Securities boosted their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "market outperform" rating in a report on Tuesday.May 7, 2024 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 5.5% Following Better-Than-Expected EarningsBioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 5.5% Higher Following Strong EarningsMay 7, 2024 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPSBioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) released its earnings results on Monday. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.06. The company had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. During the same period in the previous year, the firm posted ($0.28) EPS. The company's revenue for the quarter was up 34.9% on a year-over-year basis.May 7, 2024 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday.May 7, 2024 | finance.yahoo.comBioCryst Pharmaceuticals Inc (BCRX) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...May 7, 2024 | globenewswire.comBioCryst to Present at Upcoming Investor ConferencesMay 7, 2024 | seekingalpha.comBioCryst: Estimate-Beating Q1 But Risks Are ConsiderableMay 7, 2024 | finance.yahoo.comQ1 2024 BioCryst Pharmaceuticals Inc Earnings CallMay 6, 2024 | fool.comWhy BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on MondayMay 6, 2024 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up to $4.45BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up to $4.45May 6, 2024 | marketwatch.comBioCryst Pharma Shares Jump on Strong 1Q Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. BCRX Media Mentions By Week BCRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCRX News Sentiment▼1.190.76▲Average Medical News Sentiment BCRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCRX Articles This Week▼124▲BCRX Articles Average Week Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TSHA News Today ADAP News Today VXRT News Today ATHA News Today PASG News Today ALGS News Today KRYS News Today MDGL News Today ALKS News Today FOLD News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCRX) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
